Pharma Industry News
A collection of Pharma latest news, analysis and best practices from top business influencers and the world's most trustworthy sources.
Atyr Pharma: Q3 Earnings Snapshot
SAN DIEGO (AP) — SAN DIEGO (AP) — Atyr Pharma Inc. (ATYR) on Thursday reported a loss of $18.3 million in its third quarter. The San Diego-based company said it had a loss of $7.43 per share. Atyr Pharma shares have declined 81% since…
Nikkei Rises 0.7%, Led by Auto, Pharma Stocks
0019 GMT — Japanese stocks are higher after the Democratic sweep of U.S. Congress boosted expectations for a quick end to the Iran conflict, leading to sharply lower oil prices overnight. Auto, pharmaceutical and real-estate stocks are…
ANI Pharma (ANIP) Q3 2026 Earnings Call Transcript
President and Chief Executive Officer - Nikhil Lalwani Senior Vice President and Chief Financial Officer - Stephen Carey Senior Vice President and Head of ANI's Rare Disease Business - Christopher K. Mutz Chief Medical Officer - Gary Powell…
Acadia Pharma (ACAD) Q3 2026 Earnings Call Transcript
Senior Vice President, Investor Relations and Corporate Communications - Al Kildani Chief Executive Officer - Catherine Owen Adams Chief Commercial Officer - Tom Garner Senior Vice President and Head of Clinical Development - Sanjeev Pathak Chief…
Alembic Pharma Q2 net surges 81% to ₹335 crore
Published - November 05, 2026 04:50 pm IST - HYDERABAD Subscribe to The Hindu @ Just ₹1* Subscribe to The Hindu @ Just $4.99 *Offer only for new subscribers Alembic Pharmaceuticals shares were in the spotlight Wednesday after the generic…
Aurobindo Pharma Q2 net up 32.5% to ₹1,124 cr on higher revenue
Updated - November 05, 2026 05:04 pm IST - HYDERABAD Subscribe to The Hindu @ Just ₹1* Subscribe to The Hindu @ Just $4.99 *Offer only for new subscribers Aurobindo Pharma's consolidated net profit for the quarter ended September rose 32.5%…
Sun Pharma Shares Slip Below 20-Day EMA, Economic Times Reports
A price mismatch on The Economic Times' live page complicates its report that Sun Pharmaceutical Industries Limited shares traded beneath a 20-day EMA in early Thursday trading. At 11:06:05 p.m. EST Wednesday (04:06 UTC Thursday), The Economic…
Aurobindo Pharma Sets Quarterly Revenue Record as Q2 Profit Rises 32.5%
Aurobindo Pharma's revenue from operations reached ₹102.63 billion in the three months ended Sept. 30, 2026, a 23.9% annual increase and a new quarterly high, as consolidated profit after tax rose 32.5%. The company's unaudited results cover…
Royalty Pharma (NASDAQ:RPRX) Given New $78.00 Price Target at Citigroup
Royalty Pharma (NASDAQ:RPRX - Get Free Report) had its target price lifted by Citigroup from $70.00 to $78.00 in a research note issued to investors on Thursday, Benzinga reports. The brokerage presently has a 'buy' rating on the biopharmaceutical…
Guggenheim Has Lowered Expectations for Urogen Pharma (NASDAQ:URGN) Stock Price
Urogen Pharma (NASDAQ:URGN - Get Free Report) had its price objective lowered by analysts at Guggenheim from $58.00 to $56.00 in a note issued to investors on Thursday, Benzinga reports. The firm currently has a 'buy' rating on the stock.
Innate Pharma Q3 Earnings Call Highlights
Innate Pharma NASDAQ: IPHA said it has initiated a Phase 3 study of its lymphoma drug lacutamab and expects to present Phase 1 data for its experimental cancer treatment IPH4502 on Nov. 18, as the company outlined its third-quarter 2026 business…
NewAmsterdam Pharma (NASDAQ:NAMS) Given New $46.00 Price Target at Needham & Company LLC
NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) had its price target lowered by stock analysts at Needham & Company LLC from $48.00 to $46.00 in a report issued on Thursday, Benzinga reports. The brokerage currently has a 'buy' rating on the…
Swiss chikungunya fever patients live in close proximity
It is possible that two of the four patients were infected by the same mosquito, the Ticino cantonal medical officer stated in response to an enquiry from the Keystone-SDA news agency. The others were most likely bitten by related mosquitoes.
NewAmsterdam Pharma (NASDAQ:NAMS) Sets New 52-Week Low - Time to Sell?
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Get Free Report) hit a new 52-week low on Thursday. The stock traded as low as $19.00 and last traded at $19.8040, with a volume of 221,006 shares traded. The stock had previously closed at $20.93.
Stocks in focus, Nov 5: Alembic Pharma, Northern Arc, V2 Retail, Cupid, NALCO, Bright Outdoor, Som Distilleries, Manipal Health
Alembic Pharmaceuticals Ltd has announced the expansion of its strategic collaboration with DifGen Pharmaceuticals. Building on their existing relationship, including the joint venture in Canada, the expanded collaboration combines DifGen's…
Receive a Daily briefing on Pharma Industry News
Get Started